Vakaet, Vincent Van Hulle, Hans Vergotte, Marie Schoepen, Max Deseyne, Pieter Van Greveling, Annick Post, Giselle Speleers, Bruno Paelinck, Leen Monten, Chris
...
Published in
International journal of radiation oncology, biology, physics
Prone position for whole breast irradiation (WBI) results in lower rates of toxicity and reduced ipsilateral mean lung and heart doses. No randomized trials comparing toxicity and cosmesis at 5 years with prone and supine positioning are available. In this phase 2 open-label trial, 100 patients with large breast size requiring WBI were randomized b...
Latacz, Emily van Dam, Pieter-Jan Vanhove, Christian Llado, Laura Descamps, Benedicte Ruiz, Núria Joye, Ines Grünhagen, Dirk Van Laere, Steven Dirix, Piet
...
Published in
Seminars in cancer biology
The histopathological growth patterns (HGPs) of liver metastases of colorectal cancer and of several other tumor types predict outcome of patients in multiple studies. The HGPs of liver metastases have a prognostic but also a predictive value with one of the growth patterns, the replacement growth pattern, related to resistance to systemic treatmen...
Vanhooren, Jolien Derpoorter, Charlotte Depreter, Barbara Deneweth, Larissa Philippé, Jan De Moerloose, Barbara Lammens, Tim
Published in
Cancer Immunology, Immunotherapy
In recent decades, immunotherapy has become a pivotal element in cancer treatment. A remaining challenge is the identification of cancer-associated antigens suitable as targets for immunotherapeutics with potent on-target and few off-tumor effects. The T-cell receptor gamma (TCR γ ) chain alternate reading frame protein (TARP) was first discovered ...
Lodillinsky, Catalina Fuhrmann, Laetitia Irondelle, Marie Pylypenko, Olena Li, Xiao-Yan Bonsang-Kitzis, Hélène Reyal, Fabien Vacher, Sophie Calmel, Claire De Wever, Olivier
...
Abstract
Membrane Type 1 Matrix Metalloprotease (MT1-MMP) contributes to the invasive progression of breast cancers by degrading extracellular matrix tissues. Nucleoside diphosphate kinase, NME1/NM23-H1, has been identified as a metastasis suppressor; however, its contribution to local invasion in breast cancer is not known. Here, we report that NME...
Oltean, Teodora Van San, Emily Divert, Tatyana Vanden Berghe, Tom Saelens, Xavier Maelfait, Jonathan Takahashi, Nozomi Vandenabeele, Peter
Published in
Cell Death & Disease
RIPK3 was reported to play an important role in the protection against influenza A virus (IAV) in vivo. Here we show that the requirement of RIPK3 for protection against IAV infection in vivo is only apparent within a limited dose range of IAV challenge. We found that this protective outcome is independent from RIPK3 kinase activity and from MLKL. ...
Tosello, Valeria Bongiovanni, Deborah Liu, Jingjing Pan, Qingfei Yan, Koon-Kiu Saccomani, Valentina Van Trimpont, Maaike Pizzi, Marco Mazzoni, Martina Dei Tos, Angelo Paolo
...
Published in
Leukemia
T-cell acute lymphoblastic leukemia (T-ALL) is a highly malignant pediatric leukemia, where few therapeutic options are available for patients which relapse. We find that therapeutic targeting of GLI transcription factors by GANT-61 is particularly effective against NOTCH1 unmutated T-ALL cells. Investigation of the functional role of GLI1 disclose...
Van Hoecke, Lien Verbeke, Rein Dewitte, Heleen Lentacker, Ine Vermaelen, Karim Breckpot, Karine Van Lint, Sandra
Published in
Molecular Cancer
mRNA therapeutics have become the focus of molecular medicine research. Various mRNA applications have reached major milestones at high speed in the immuno-oncology field. This can be attributed to the knowledge that mRNA is one of nature’s core building blocks carrying important information and can be considered as a powerful vector for delivery o...
Garcia, E G Veloso, A Oliveira, M L Allen, J R Loontiens, S Brunson, D Do, D Yan, C Morris, R Iyer, S
...
Published in
Leukemia
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes and is largely driven by the NOTCH/MYC pathway. Yet, additional oncogenic drivers are required for transformation. Here, we identify protein tyrosine phosphatase type 4 A3 (PRL3) as a collaborating oncogenic driver in T-ALL. PRL3 is expressed in a large fraction o...
Alzeibak, Razan Mishchenko, Tatiana A. Shilyagina, Natalia Y. Balalaeva, Irina V. Vedunova, Maria V. Krysko, Dmitri V.
Published in
Journal for Immunotherapy of Cancer
The past decade has witnessed major breakthroughs in cancer immunotherapy. This development has been largely motivated by cancer cell evasion of immunological control and consequent tumor resistance to conventional therapies. Immunogenic cell death (ICD) is considered one of the most promising ways to achieve total tumor cell elimination. It activa...
Lebbé, Céleste Italiano, Antoine Houédé, Nadine Awada, Ahmad Aftimos, Philippe Lesimple, Thierry Dinulescu, Monica Schellens, Jan H. M. Leijen, Suzanne Rottey, Sylvie
...
Background Pimasertib is a selective, potent mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor. Objectives The aim of this study was to describe the efficacy, safety, and pharmacodynamics of pimasertib at pharmacologically active doses in a cohort of patients with locally advanced/metastatic melanoma from a first-in-human study of pimaser...
